THE Therapeutic Goods Administration (TGA) has posted a new chemical entity (NCE)registration and two 'extension of indication' registrations for April on its website.
The NCE is Afstyla (lonoctocog alfa [recombinant single-chain coagulation factor VIII]) vy CSL Behring Australia for haemophilia.
Extensions of indication were granted for AbbVie's Viekira Pak-RBV (paritaprevir/ritonavir/ombitasvir & dasabuvir & ribavirin) and Viekera Pak (paritaprevir/ritonavir/ombitasvir & dasabuvir) for hepatitis C treatments.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Apr 17